Could a higher dose of rifampicin cut TB treatment time for kids?
NCT ID NCT07656012
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests whether a higher dose of the drug rifampicin can safely shorten tuberculosis treatment for children aged 3 months to 10 years. About 230 children with drug-susceptible TB will receive either the standard or a higher rifampicin dose, with treatment duration adjusted. The goal is to find a shorter regimen that works as well as the current standard, potentially improving outcomes for children worldwide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Socios en Salud Sucursal Peru
Lima, Peru
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rifampicin (higher dose) combined with isoniazid, pyrazinamide, and ethambutol
What this could lead to
If successful, this could lead to a shorter, more convenient treatment for children with tuberculosis, reducing the burden on families and healthcare systems.
What could go wrong
This is a Phase 2 trial with only 230 children, so results are preliminary. Higher doses may cause more side effects, and shorter treatment might not cure everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.